Zum Hauptinhalt springen
| Hans-Günter Meyer-Thompson | Amphetamine

USA. FDA rejects MDMA as a psychedelic treatment for PTSD

USA. FDA rejects MDMA as a psychedelic treatment for PTSD

The Food and Drug Administration rejected MDMA as a treatment for post-traumatic stress disorder on Friday, in a blow to drug activists and veterans who’ve long campaigned for the psychedelic treatment. Although two Phase 3 trials suggested the treatment was effective, strong opposition by an agency scientific advisory committee in June and allegations of missing adverse event data and research bias may have doomed the application by Lykos Therapeutics. (Stat News, USA, 09.08.2024)

https://www.statnews.com/2024/08/09/mdma-fda-rejection-of-ptsd-treatment-lykos-psychedelic/